Contact irradiation of eye tissues within photodynamic therapy involved in treatment of infectious corneal ulcers

FIELD: medicine.

SUBSTANCE: contact irradiation of eye tissues within photodynamic therapy involved in infectious corneal ulcers is ensured by application of a light guide nozzle with a circular border at its bottom. Application and exposition of a photosensitiser is followed with application of a staining agent on the nozzle edge. Then the nozzle is placed on the corneal ulcer region that is followed with contact laser irradiation with fields of diametre 3 mm herewith covering the adjacent fields by 5-10% of the area. The nozzle is sequentially circled within the corneal ulcer region from periphery to the middle.

EFFECT: possibility to limit the area of one laser radiation spot with specified dimensions, thus maintaining the constant distance of the light guide end face to the irradiated surface during procedure, achieved accurate visualisation of the irradiated regions, limited area of laser irradiation by desired region, managed infectious processes, epithelised corneal ulcers with forming the smooth opacity, and prevented inflammatory complications.

 

The invention relates to medicine and can be used in ophthalmology for contact exposure to the eye tissue during photodynamic therapy during treatment of infectious corneal ulcers.

Corneal ulcer belongs to the category of serious eye diseases that are difficult to treat and almost always ending with a visual impairment.

Pitting can capture any part of the cornea, it is especially the defeat of the Central zone, it is harder treated and often results in loss of vision.

Among the infectious lesions of the cornea according to the frequency in the first place are herpes viral, bacterial, fungal and parasitic (Acanthamoeba).

Difficulties in the treatment of infectious corneal ulcers are associated with a number of reasons, the most important of which are the increasing antibiotic resistance of microorganisms, high risk of loss of visual function due to gross scarring and the development of inflammatory complications (endophthalmitis, panophthalmitis) (Michuk .F. Therapeutic algorithms with infectious corneal ulcers, " Vestn. oftalmol. - 2002. - T. No. 3. - P.35-37; Shaimova VA Suppurative corneal ulcers. (Clinic, diagnostics, treatment): author. descend. the honey. Sciences. - Chelyabinsk, 1999).

Photodynamic therapy (PDT) is a highly effective method that is currently successful PR is changing in many clinical areas. Photodynamic therapy is based on the selective accumulation of a photosensitizer (PS) in the target cells and its activation by laser radiation with a wavelength corresponding to the peak absorption of this FS. Subsequent photochemical reactions lead to the formation of reactive oxygen species and cell death. Antimicrobial PDT effect was discovered more than 100 years ago. Currently, the active development of this direction in the treatment of various infectious diseases (Hamblin, .R., and T. Hasan. Photodynamic therapy: a new antimicrobial approach to infectious disease? // Photochem. Photobiol. Sci. - 2004. - Vol.3. - P. 436-450.).

Based on the foregoing, the use of PDT for treatment of infectious corneal ulcers is reasonable. The efficacy of PDT depends on many factors, including the dose of laser irradiation. In addition, the principle is the strict limitation of the irradiation zone boundaries of the target zone in order to avoid phototoxic damage to surrounding tissues intact.

Standard laser irradiation during photodynamic therapy of infectious corneal ulcers is performed using a fiber optic conductor, fields, consistently, with overlapping of adjacent fields 5-10% of the area (White Y.A., Tereshchenko A.V., Plahotnii M.A., Yudin N.N., Soloviev D.K. Photodynamic therapy of suppurative corneal ulcers // Aroseva reading: proceedings of all-Russian Conf. Ed., Kotelnikova, Higuerote, Vammala. - Samara, 2007. - S-272). However, using conventional laser optical fiber, it is impossible to accurately control the distance to the irradiated surface, which causes the change in delivered dose of laser energy, as well as to visualize the irradiated areas, limiting the scope of the irradiation target area. All this adversely affects the efficiency of PDT.

Therefore, the developing method of the contact exposure of the eye tissue during photodynamic therapy during treatment of infectious corneal ulcers is relevant.

Not known to the authors way of the contact exposure of the eye tissue during photodynamic therapy during treatment of infectious corneal ulcers.

The objective of the invention is a developing method of the contact exposure of the eye tissue during photodynamic therapy during treatment of ulcers of the cornea.

The technical result is to limit the area of a single spot of laser radiation set sizes, maintaining a constant distance from the end face of the fiber to the irradiated surface during the procedure, a clear visualization of the irradiated areas, limiting the field of laser irradiation of the target area, stopping the infection epithelialization of ulcers of the cornea with the formation of the soft dimness, the absence of inflammatory complications.

The basis of the ski is achieved due to the fact, that:

1) the fiber is at a constant distance to the irradiated surface during the entire procedure;

2) the area of a spot of laser radiation is severely restricted;

3) irradiated areas clearly visualized by dye;

4) conducting contact exposure corneal ulcers fields of laser radiation, with overlapping of adjacent fields 5-10% of the area, sequentially, in a circle from the periphery to the centre helps limit the field of laser irradiation of the target area;

5) conducting contact exposure areas corneal ulcers locally activates accumulated FS, causing a photochemical reaction resulting in the death of microorganisms, promotes epithelialization of the ulcer and tender rupavati.

For the implementation of the proposed method using the nozzle on the light guide, which contains a transparent cylindrical body-emphasis, the locking ring and the locking nut. Case-emphasis consists of the upper part of the neck, which is applied to male threads, and the lower hollow part. In the upper part of the body-stops along the axis of rotation is a through channel for the introduction of the fiber, the lower part of the body-emphasis intended for contact with the irradiated surface and ends in a circular edge-timer at the end. The fiber is tightly secured in the channel of the upper part of the body-emphasis oposredstvovaniya ring and the locking nut, which is wrapped around the threads of the neck of the upper part of the body-rest, while the end face of the optical fiber extends into the cavity housing-stops.

The size of emphasis: length - 40 mm, 24 mm - length top, 6 mm is the length of the neck; diameter, except cervix is 8 mm, the diameter at the neck top - 5 mm. Internal diameter of the bottom part of the device is chosen accordingly to the required diameter of the laser spot and is 3 mm Thick circular edge-timer - 0,3 mm Diameter through the channel of the upper part of the body should be sufficient for introducing the fiber.

Case-emphasis can be performed, for example, polymethyl methacrylate, polytetrafluoroethylene-4, the retainer ring is made of silicone, lock nut - stainless steel.

Contact irradiation of eye tissues under the proposed method during photodynamic therapy during treatment of corneal ulcers is as follows.

Calculate the required therapeutic dose of laser irradiation and verify it by measuring the output power nozzles using a power meter. If necessary, correct the settings of the laser.

After local application and exposure of PS on the edge-timer put 1%aqueous-alcoholic solution of brilliant green, set the nozzle end of the bottom part with kromko is a timer on the area of corneal ulcers and hold the contact irradiation fields, with overlapping of adjacent fields 5-10% of the area, by successively moving the nozzle within the target zone (the circle from the periphery to the center of the corneal ulcers). The boundaries of each field are visualized by coloring matter.

The invention is illustrated by the following data.

Photodynamic therapy with the application of the proposed method of contact exposure of eye tissues was performed in 5 patients with purulent corneal ulcer (according to microbiological studies in two cases noted the growth of Staphylococcus aureus in two - Escherihia coli and one Enterococcus faecalis). During the procedure in all cases: the distance from the end face of the fiber to the irradiated surface remained unchanged, the area of one spot of the laser radiation is visually consistent with the internal space of the case base-emphasis irradiated areas were clearly marked by the dye deposited on the edge-timer, which helped to limit the scope laser irradiation of the target area (the area of corneal ulcers).

At the control examination on the 14th day all of the patients showed complete epithelialization of the ulcer with the formation of gentle opacities in the corneal stroma. The growth of microflora during sowing of the conjunctival cavity was absent. The observation period up to 3 months without signs of inflammation.

So the m way the claimed invention provides for limiting the area of a single spot of laser radiation set sizes, maintaining a constant distance from the end face of the fiber to the irradiated surface during the procedure, a clear visualization of the irradiated areas, limiting the field of laser irradiation of the target area, mild infection, ulcer epithelization of the cornea with the formation of the soft dimness, the absence of inflammatory complications.

Method of contact exposure to the eye tissue during photodynamic therapy during treatment of infectious corneal ulcers, which consists in the fact that they are carrying out laser irradiation fields with a diameter of 3 mm with overlapping of adjacent fields 5-10% of the area by successively moving the nozzle to the optical fiber with the dye on the edge-the timer within the field of corneal ulcers in a circle from the centre to the periphery.



 

Same patents:

FIELD: medicine.

SUBSTANCE: integrated treatment of malignant tumour pleura involvement accompanied with exudative pleurisy is ensured with argon-plasma electrocoagulation of pleura at power 60-90 Wt and argon consumption 2.0-2.4 l/min followed with intraoperative photodynamic therapy. A photosensitiser is Photoditasine dosed 1.5 mg/kg. The irradiation involves diode laser of wavelength 662 nm and power density 300 mWt/cm2, at total energy dose 400 J/cm2. In addition, it is combined with hyperthermic intrapleural chemoperfsion of cisplatin 100 mg in 1500-3000 ml of 0.9 % sodium chloride solution at temperature 42C within 60 minutes at feed rate 1200 ml/min.

EFFECT: reduced tumour weight, terminated exudation and protein loss, reduced inflammation, intoxication and pain syndrome, local and systemic cytostatic action of cisplatin.

3 ex

FIELD: medicine.

SUBSTANCE: therapy involves exposure on acupunctural points of gall bladder in combination with conventional conservative therapy. Exposure on acupunctural points implies laser radiation of frequency 1425-1575 Hz, wavelength 0.83-0.89 mcm, unit impulse power 5-6 Wt, unit impulse duration 110-160 ns. Acupunctural points are tonic by exposure within 4-6 seconds, while sedation is ensured by exposure within 16-18 seconds. Then right hypochondrium is exposed to pulse magnetic field of induction 22.5-37.5 mTl, frequency 49.5-50.5 Hz, duration 20-25 minutes. The epigastrium is exposed to variable magnetic field of induction 22.5-37.5 mTl, frequency 49.5-50.5 Hz, and duration 20-25 minutes. The therapeutic course is 10-12 days.

EFFECT: method reduces fatal outcome rate ensured by exacerbation management and elective surgery.

2 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: said device contains a transparent cylindrical support case, a retainer ring and a lock nut. The support case comprises a necked top with an external thread and a light guide port, and a hollow bottom with a circular marking edge at the end face. When the device is applied for photodynamic therapy of intraocular neoplasms, the marking edge is covered with brilliant green. The device is mounted with its end face of the bottom with a marking edge on sclera exposed to contact transscleral laser irradiation herewith covering the adjacent fields by 15-20% of the area through sequential relocation of the device from periphery to the middle within projection of tumour base on sclera and covering 2 mm of adjacent tissues.

EFFECT: application of group of inventions provides limitation of the area of one laser radiation spot in specified dimensions, herewith maintaining constant distance of the light guide end face to irradiated surface within procedure, accurate visualisation of the irradiated sites, with limiting the area of a laser irradiation by desired region.

2 cl, 1 dwg

FIELD: medicine.

SUBSTANCE: invention concerns medicine, particularly obstetrics and hestosis treatment for the pregnant. Method involves endovascular laser irradiation of blood for six days. Further, polyphepan is administered internally for eight days in the dosage of 0.5 g per kg of pregnant body weight for 3-4 times per day.

EFFECT: therapeutic effect with reduced treatment duration and medication load on organism of the pregnant due to the selected regimen.

1 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, laser medicine, and can be applied in treatment of trophic ulcers of venous etiology. Method involves processing of ulcer surface and skin around ulcer by air and gas flow with nitrogen oxide content 2000 ppm or more at 40C, with 10 second exposition per 1 cm2. Further, 0.1% Radachlorine gel is applied as photo sensitiviser in amount of 0.2 g per 1 cm2 with 60 minutes exposition. Then laser emission of 0.665 mcm wavelength and light energy dosage of 150-200 J/cm2 is applied at 3-5 mm distance from wound surface. Afterwards intravenous blood irradiation is performed over cubital vein by laser emission of 0.632 mcm wavelength and radiation power of 5 mW with 15 minutes exposition. Treatment course comprises 10 daily procedures of air and gas flow processing and intravenous blood irradiation and 5-8 photodynamic therapy procedures performed over 2 day interval.

EFFECT: improved neurotrophic regulation of damaged tissues, antimicrobe effect, reduced frequency of purulent complications, improved blood flow properties, prevented resistance of ulcer microflora to antibiotics and drugs, prevented dysplasia, cicatrical changes and skin malignisation around trophic ulcer.

4 cl, 1 ex

FIELD: medical equipment.

SUBSTANCE: invention concerns medical equipment and can be applied in cancer tissue treatment in various organs of biological objects. Device includes semiconductor laser diode, clock generator, semitransparent mirror, comparator, first, second and third direct current amplifiers, differentiating amplifier, discriminating amplifier, first and second photo receivers, delay line, analog to digital converter, programmed permanent memory, first and second binary code comparators, first and second control systems of secondary power sources, first and second secondary power sources and light panel/indicator. Biological object is positioned in line between semiconductor laser, semitransparent mirror and second photo receiver.

EFFECT: extended range of technical devices for laser cancer therapy.

4 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to laser therapy. The first stage of the therapy involves introduction of medicines and intravenous laser blood exposure by installing a needle in one solution transfusion system for quartz fibre of diametre 0.7 mm through which the patient is exposed to helium-neon laser of power 1.2 mW at exposition 90 minutes within seven daily procedures. The second stage includes paravertebral block within herniated disk localisation in projection of herniated disk. Quartz fibre of diametre 0.7 mm is introduced through a puncture needle to the level of surface musculofascial layer. Injection of solution is immediately followed with irradiation with helium-neon laser of power 1.2 mW at exposition 80 minutes within seven daily procedures. Medicines within solution transfusion system are as follows: Trental 5 ml, Actovegin 5 ml, 15% Xantinol Nicotinate 2 ml, vitamin B1 2 ml alternated with vitamin B6 2 ml, 5% vitamin C 3 ml dissolved in physiologic saline 150 ml. Paravertebral block of the first day includes 5% glucocorticoid Diprospan 1 ml combined with 2% Lidocaine. For the following days 2% Lidocaine is used.

EFFECT: method allows terminating inflammatory process, ensuring stable pain management.

3 ex

FIELD: medicine.

SUBSTANCE: therapy of secondary lower limb lymphodema refers to medicine, namely to clinical lymphology. The oatient is exposed to laser light of wavelength 0.6328 mcm combined with intravenous laser irradiation of power 1.2 mW and exposition 90 minutes and intravenous introduction of medicine solutions: Trental, Actovegin, Pheopolyglukine, vitamin B, C complexes, 0.15% xantinol nicotinate. Procedures are daily at seven procedures per course.

EFFECT: therapy provides stable reduction of secondary lower limb lymphodema without therapeutic by-effects, prevents recurrence.

2 cl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, to neurology. The therapy involves taking the medicines improving cerebral blood circulations. Pharmacotherapy is combined with exposure to laser light within anconeus and popliteal fold regions. Laser puncture covers the points VB 20 and VB 21 symmetrically downright. Laser light is characterised with wavelength 0.89 mcm, power 3 mW and frequency 600 Hz. Herewith light exposure is 1 minute per each point and 2-3 minutes per elbow and popliteal folds. Therapeutic course is 10 days twice every second month.

EFFECT: method reduces treatment time.

3 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, oncology, surgery, radiology, physical therapy and can be used for treating patients with larynx cancer. Area of radiation and surrounding tissues is exposed to infrared laser irradiation. From first day of radioreaction diagnostics, exposure to infrared laser irradiation with constant magnetic field with magnetic induction intensity within 20 mTa, recurrence frequency of pulse laser irradiation of infrared spectrum within 80 Hz, power 0.5-1.0 W on all zone of irradiation is performed with defocused ray for 30-120 seconds. Course includes 3-8 procedures with further application on irradiation zones and intake of a teaspoon of cedar nut oil and before going to bed daily during the whole course of radiation therapy.

EFFECT: method allows to increase efficiency of treatment of early radioreactions and prevent development of later radiation damage reducing severity and frequency of their development.

2 ex

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-0.3 ml of photosensitizing gel preliminarily activated with laser radiation, after having removed neovascular membrane. The photosensitizing gel is based on a viscoelastic of hyaluronic acid containing khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-2% by mass. The photosensitizing gel is in vitro activated with laser radiation having wavelength of 661-666 nm during 3-10 min with total radiation dose being equal to 100-600 J/cm2. The gel is introduced immediately after being activated. To compress the retina, vitreous cavity is filled with perfluororganic compound or air to be further substituted with silicon oil. The operation is ended with placing sutures on sclerotomy and conjunctiva areas. Compounds like chealon, viscoate or hyatulon are used as viscoelastic based on hyaluronic acid. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity.

EFFECT: excluded recurrences of surgically removed neovascular membrane and development of proliferative retinopathy and retina detachment; retained vision function.

3 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: method involves making incision in conjunctiva and Tenon's capsule of 3-4 mm in size in choroid hemangioma projection to sclera 3-4 mm far from limb. Tunnel is built between sclera and Tenon's capsule to extrasclerally introduce flexible polymer magnetolaser implant through the tunnel to the place, the choroid hemangioma is localized, after performing transscleral diaphanoscopic adjustment of choroid hemangioma localization and size, under visual control using guidance beam. The implant has permanent ring-shaped magnet in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 2-3 mTesla units intensity. It is arranged with its north pole turned towards the choroid hemangioma so that extrascleral implant laser radiator disposition. The other end of the implant is sutured to sclera 5-6 mm far from the limb with two interrupted sutures through prefabricated openings. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. 0.1-1% khlorin solution is injected in intravenous bolus dose of 0.8-1.1 mg/kg as photosensitizer and visual control of choroid hemangioma cells fluorescence and fluorescent diagnosis methods are applied. After saturating choroid hemangioma with the photosensitizer to maximum level, transscleral choroid hemangioma laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm with total radiation dose being equal to 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the intraocular neoplasm, repeated laser irradiation of the choroid hemangioma is carried out with radiation dose of 30-60 J/cm2.

EFFECT: enhanced effectiveness of treatment.

4 cl

FIELD: medicine.

SUBSTANCE: method involves creating tunnel between sclera and Tenon's capsule in intraocular neoplasm projection. Intraocular neoplasm localization and size is adjusted by applying transscleral diaphanoscopic examination method. 0.1-0.3 ml of photosensitizing gel based on viscoelastic of hyaluronic acid, selected from group containing chealon, viscoate or hyatulon, is transsclerally introduced into intraocular neoplasm structure using special purpose needle in dosed manner. The photosensitizing gel contains khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-1% by mass. Flexible polymer magnetolaser implant is extrasclerally introduced into the built tunnel in intraocular neoplasm projection zone under visual control using guidance beam. The implant has permanent ring-shaped magnet axially magnetized and producing permanent magnetic field of 3-4 mTesla units intensity, in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The implant is arranged with its north pole turned towards the intraocular neoplasm so that implant laser radiator lens is extrasclerally arranged in intraocular neoplasm projection zone. The implant light guide is sutured to sclera 5-6 mm far from the limb with single interrupted suture. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transscleral intraocular neoplasm laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm. The treatment course being over, the flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, neodymium-iron-boron or samarium-iron-nitrogen. 0.1-1% khlorin solution as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is additionally intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg and repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2 15-20 min later during 30-90 s.

EFFECT: complete destruction of neoplasm; excluded its further growth.

4 cl

FIELD: medicine.

SUBSTANCE: method involves applying transscleral diaphanoscopic examination method for adjusting intraocular neoplasm localization and size. Rectangular scleral pocket is built 2/3 times as large as sclera thickness which base is turned from the limb. Several electrodes manufactured from a metal of platinum group are introduced into intraocular neoplasm structure via the built scleral pocket. Next to it, intraocular neoplasm electrochemical destruction is carried out in changing electrodes polarity with current intensity of 100 mA during 1-10 min, and the electrodes are removed. Superficial scleral flap is returned to its place and fixed with interrupted sutures. 0.1-2% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transpupillary laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2. the operation is ended with placing sutures on conjunctiva. Platinum, iridium or rhodium are used as the metals of platinum group. The number of electrodes is equal to 4-8. 0.1-1% khlorin solution, selected from group containing photolon, radachlorine or photoditazine, is additionally repeatedly intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2.

EFFECT: complete destruction of neoplasm; excluded tumor recurrence; reduced risk of tumor cells dissemination.

3 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: the present innovation deals with treating vascular cutaneous neoplasms, such as nevus flammeus and gemangiomas. Light-thermal impact at energy ranged 39-47 J/sq. cm should be performed in two stages, and between them, 2-3 wk after the onset of vascular resistance at the first stage one should perform beta-therapy daily for 2-3 d at single dosage being 20 g. Then, 3 wk later it is necessary to conduct the second stage of light-thermal impact by starting at energy value being 42 J/sq. cm, not less. The method enables to shorten therapy terms due to applying combined method to affect vascular cutaneous neoplasms.

EFFECT: higher therapeutic and cosmetic effect.

1 ex

FIELD: medicine.

SUBSTANCE: method involves intravitreously introducing two electrodes into intraocular neoplasm after carrying out vitrectomy and retinotomy to expose the intraocular neoplasm. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with current intensity of 100 mA during 1-10 min or 10 mA during 10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2.The transformed retina and tumor destruction products are intravitreally removed. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. Another embodiment of the invention involves adjusting position and size of the intraocular neoplasm in trans-scleral diaphanoscopic way. Rectangular scleral pocket is built above the intraocular neoplasm to 2/3 of sclera thickness with its base turned away from limb. Several electrodes are introduced into intraocular neoplasm structure via the built bed. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with the same current intensity in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. Superficial scleral flat is returned to its place and fixed with interrupted sutures. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg after having carried out vitrectomy and retinotomy. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2. The transformed retina and tumor destruction products are intravitreally removed using vitreotome. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. The number of electrodes is equal to 4-8.

EFFECT: reduced risk of metastasizing.

4 cl, 13 dwg

FIELD: medicine.

SUBSTANCE: method involves building tunnel to posterior eyeball pole in inferoexterior and superexterior quadrants. The tunnel is used for implanting flexible polymer magnetolaser implant to the place, the subretinal neovascular membrane is localized. The implant has a permanent magnet shaped as a cut ring and is provided with drug delivery system and a short focus scattering lens of laser radiator connected to light guide. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 5-7 mTesla units intensity. It is arranged with its north pole turned towards sclera at the place of the subretinal neovascular membrane projection with extrascleral arrangement of laser radiator lens membrane being provided in the subretinal neovascular membrane projection area. The other implant end is sutured to sclera 5-6 mm far from the limb via holes made in advance. The implant is covered with conjunctiva and retention sutures are placed thereon. Light guide and drug supply system lead is attached to temple with any known method applied. Drugs are supplied via the implant drug supply system in retrobulbary way in any order. Triombrast is given in the amount of 0,4-0,6 ml and dexamethasone or dexone in the amount of 0,4-0,6 ml during 3-4 days every 12 h. 0.1-1% aqueous solution of khlorin is intravenously introduced at the third-fourth day after setting the implant as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, at a bolus dose of 0.8-1.1 mg/kg. Visual control of subretinal neovascular membrane cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the subretinal neovascular membrane with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at general dose of 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the subretinal neovascular membrane via laser light guide and implant lens, repeated laser irradiation of the subretinal neovascular membrane is carried out with radiation dose of 30-60 J/cm2.

EFFECT: accelerated subretinal edema and hemorrhages resorption; regression and obliteration of the subretinal neovascular membrane; prolonged vision function stabilization.

6 cl

FIELD: medicine.

SUBSTANCE: method involves filling vitreous cavity with perfluororganic compound. Two electrodes manufactured from platinum group metal are intravitreally, transretinally introduced into intraocular neoplasm. Electrochemical destruction is carried out with current intensity of 10-100 mA during 1-10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2 in perfluororganic compound medium. The transformed retina and tumor destruction products are intravitreally removed with perfluororganic compound volume being compensated with its additional introduction. Boundary-making endolasercoagulation of retinotomy area is carried out. The perfluororganic compound is substituted with silicon oil. The operation is ended in placing sutures over sclerotmy areas and over conjunctiva. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity. Platinum, iridium or rhodium are used as the platinum group metals.

EFFECT: complete destruction of neoplasm; reduced dissemination risk.

6 cl, 12 dwg

FIELD: medicine, applicable for stopping of pains of various nature.

SUBSTANCE: the device has a quantum-mechanical oscillator located in a casing, magnet, vessel for medicinal agent and a hollow cylinder. The magnet is installed between the oscillator and the vessel. Positioned in the vessel is a hollow cylinder having through holes on its surface.

EFFECT: quick and absolute anestesia.

2 ex, 1 dwg

FIELD: medicine.

SUBSTANCE: method involves administering laser radiation therapy once a day using low intensity pulsating radiation of wavelength equal to 890nmand power density of 0.03 mW/cm2. Injured organ projection to frontal abdominal wall is exposed to radiation at the first laser therapy stage in two fields acting upon each field for 2 min with radiation pulse succession frequency equal to 80 Hz in applying stable contact-type method. Total treatment dose on two fields is equal to 0.008 J/cm2. The second laser therapy stage begins immediately after having finished the first one in applying radiation along the large intestine path using labile contact-type method in a way that radiation pulse succession frequency equal to 80 Hz is applied first during 1 min and then frequencies of 600, 150 and 300 Hz are applied also during 1 min, respectively. Total treatment dose is equal to 0.032 J/cm2 at the second stage. Total treatment dose is equal to 0.04 J/cm2 at both stages.

EFFECT: enhanced effectiveness in inhibiting dysbacteriosis; reduced frequency of postoperative complications.

Up!